• Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis

     
  • Late-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseases

     
  • Rheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trial

     
  • Safety and translational data support AlloNK's potential as an outpatient-administered, community-compatible deep B-cell depleting therapy

     
  • U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for the treatment of refractory rheumatoid arthritis

     
  • Artiva to host virtual webcast today at 8:15 am EDT, featuring Dr. Paul Emery, Arthritis UK professor of rheumatology at the University of Leeds